CYCN Cyclerion Therapeutics, Inc.
Healthcare$3.20+0.63%ClosedMarket Cap: $13.9M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.97
P/S
6.91
EV/EBITDA
-1.64
DCF Value
$0.96
FCF Yield
-26.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-337.4%
Net Margin
-264.7%
ROE
-62.1%
ROA
-62.0%
ROIC
-99.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-3.2M | $-3.2M | $— | — |
| Q4 null | $1.0M | 100.0% | $-838.0K | $-799.0K | $— | — |
| FY null | $2.1M | 100.0% | $-5.0M | $-3.5M | $— | — |
| Q3 null | $875.0K | 100.0% | $-1.0M | $-976.0K | $— | — |
| Q2 null | $93.0K | 100.0% | $-1.7M | $-324.0K | $— | — |
| Q1 null | $81.0K | 100.0% | $-1.5M | $-1.4M | $— | — |
| Q4 null | $1.8M | 100.0% | $502.0K | $530.0K | $— | — |
| FY null | $2.0M | 100.0% | $-3.6M | $-3.1M | $— | — |
| Q3 null | $194.0K | 100.0% | $-1.1M | $-723.0K | $— | — |
| Q2 null | $0.00 | NaN% | $-1.4M | $-1.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.6M | $-1.5M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-1.8M | $-1.7M | $-0.68 | — |